

**P&T Motion History
Asthma Controller / COPD Drugs**

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
beclomethasone [A] budesonide [A] ciclesonide [A] flunisolide [A] fluticasone furoate [A] fluticasone propionate [A] mometasone DPI pwdr [A] mometasone MDI aerosol [A]	Inhaled Corticosteroids After considering the evidence of safety, efficacy and special populations for the treatment of Asthma, I move that beclomethasone [A] budesonide [A] ciclesonide [A] flunisolide [A] fluticasone furoate [A] fluticasone propionate [A] mometasone MDI aerosol [A] mometasone DPI powder [A] are safe and efficacious for the treatment of their approved indications. Inhaled corticosteroids can be subject to therapeutic interchange in the Washington preferred drug list. Motion: Johnson 2 nd : Bowman All delivery systems and indications will be included for all drugs.	December 19, 2018	Yes Chew Storhaug	Yes Brown Chew	Passed unanimous
		December 20, 2017	Yes Johnson Sanderson	Yes Chew Storhaug	Passed unanimous

Bold = new this update, Grey = not reviewed, cannot be included in motion
 [A] = Approved for Asthma, [C] = Approved for COPD
 12/20/2018

**P&T Motion History
Asthma Controller / COPD Drugs**

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
arformoterol [C] formoterol neb soln [C] formoterol DPI pwdr [A,C] indacaterol [C] olodaterol [C] salmeterol [A,C]	Long Acting Beta Agonists After considering the evidence of safety, efficacy and special populations for the treatment of Asthma and COPD, I move that arformoterol [C] formoterol nebulizer sol [C] formoterol pwdr [A,C] indacaterol [C] olodaterol [C] salmeterol [A,C] are safe and efficacious for the treatment of COPD and when used in the combination with inhaled corticosteroids for the treatment of asthma. Long Acting Beta Agonists can be subject to therapeutic interchange in the Washington preferred drug list if the preferred drug is approved for the condition being treated. Motion: Figueroa 2 nd : Harvey	December 19, 2018	Yes Chew Storhaug	Yes Lee Park	Passed unanimous
		December 20, 2017		Yes Johnson Figueroa	Passed unanimous

Bold = new this update, Grey = not reviewed, cannot be included in motion
 [A] = Approved for Asthma, [C] = Approved for COPD
 12/20/2018

**P&T Motion History
Asthma Controller / COPD Drugs**

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
montelukast [A] zafirlukast [A] zileuton [A]	Leukotriene Modifiers After considering the evidence of safety, efficacy and special populations for the treatment of asthma, I move that montelukast, zafirlukast, and zileuton are efficacious. Montelukast and zafirlukast may be associated with a lower incidence of hepatic toxicity than zileuton. Zileuton shall not be a preferred drug on the Washington Preferred drug list. Leukotriene modifiers can be subject to therapeutic interchange on the Washington Preferred Drug List for the indication of asthma. Motion: Klingel 2 nd : Smith	December 19, 2018	Yes Chew Storhaug	Yes Brown Storhaug	Passed unanimous
		December 20, 2017		Yes Brown Chew	Passed unanimous

**P&T Motion History
Asthma Controller / COPD Drugs**

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
<u>ICS/LABA</u> fluticasone propionate/ salmeterol DPI [A,C] fluticasone propionate/ salmeterol MDI [A] budesonide/formoterol [A,C] mometasone furoate/formoterol furoate [A] fluticasone furoate/vilanterol [A,C]	ICS/LABA Combinations After considering the evidence of safety, efficacy and special populations for the treatment of Asthma and COPD, I move that fluticasone propionate/salmeterol DPI and MDI [A,C], budesonide/ formoterol [A,C], fluticasone furoate/vilanterol [A, C] and mometasone furoate/formoterol [A] are safe and efficacious for the treatment of their approved indications. Long Acting Beta Agonist Combination with ICS products can be subject to therapeutic interchange in the Washington preferred drug list if the preferred drug is approved for the condition being treated. Motion: Johnson 2 nd : Bowman	December 19, 2018	Yes Chew Storhaug	Yes Schwilke Lee	Passed unanimous
		December 20, 2017		Yes Figuroa Schwilke	Passed unanimous

**P&T Motion History
Asthma Controller / COPD Drugs**

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
<u>LAMA/LABA</u> indacaterol/glycopyrrolate [C] olodaterol/tiotropium [C] umeclidinium/vilanterol [C] <u>ICS/LAMA</u> fomoterol/glycopyrrolate [C] <u>ICS/LAMA/LABA</u> fluticasone/umeclidinium/vilanterol [C]	LAMA/LABA Combinations After considering the evidence of safety, efficacy and special populations for the treatment of Asthma and COPD, I move that indacaterol/glycopyrrolate [C], olodaterol/tiotropium [C], and umeclidinium/vilanterol [C] are safe and efficacious for the treatment of their approved indications. Long Acting Beta Agonist Combination with LAMA products can be subject to therapeutic interchange in the Washington preferred drug list if the preferred drug is approved for the condition being treated. Motion: Johnson 2 nd : Chew	December 19, 2018	Yes Chew Storhaug	Yes Figuroa Chew	Passed unanimous
<u>LAMA/LABA</u> indacaterol/glycopyrrolate [C] olodaterol/tiotropium [C] umeclidinium/vilanterol [C]		December 20, 2017		Yes Chew Brown	Passed unanimous

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
roflumilast [C]	Phosphodiesterase-4 Inhibitor After considering the evidence of safety, efficacy and special populations for the treatment of COPD, I move that roflumilast [C] is safe and efficacious for the treatment of COPD. Phosphodiesterase-4 inhibitors can be	December 19, 2018	Yes Chew Storhaug	Storhaug Schwilke	Passed unanimous
		December 20, 2017		Yes Johnson Chew	Passed unanimous

Bold = new this update, Grey = not reviewed, cannot be included in motion
[A] = Approved for Asthma, [C] = Approved for COPD
12/20/2018

P&T Motion History
Asthma Controller / COPD Drugs

	subject to therapeutic interchange in the Washington preferred drug list. Motion: Harvey 2 nd : Johnson				
--	--	--	--	--	--

**P&T Motion History
Asthma Controller / COPD Drugs**

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
aclidinium [C] glycopyrrolate [C] tiotropium DPI pwdr [C] tiotropium SMI mist [A,C] umeclidinium [C]	Long-acting Muscarinic Antagonists (LAMA) After considering the evidence of safety, efficacy and special populations for the treatment of Asthma and COPD, I move that aclidinium [C], glycopyrrolate [C], tiotropium DPI powder [C], tiotropium SMI mist [A,C] and umeclidinium [C] are safe and efficacious for the treatment of their approved indications. LAMAs can be subject to therapeutic interchange in the Washington preferred drug list. Motion: Chew 2nd: Smith	December 19, 2018	Yes Chew Storhaug	Yes Schwilke Storhaug	Passed unanimous
		December 20, 2017		Yes Schwilke Storhaug	Passed unanimous